Page 5 - Subgroup Analysis News Today

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.

Summarizing the recent findings to clarify the predictive ability of cardio-ankle vascular index in longitudinal studies. Read more

/PRNewswire/ -- Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the...

Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe...

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV)

24.08.2022 - Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan ... Seite 1

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June

New subgroup analyses presented at Digestive Disease Week (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body